Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Trajenta | Linagliptin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | ||
| Incivek | Telaprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Edurant | Rilpivirine | HIV infection | List | Complete | ||
| Aclasta | Zoledronic acid | Osteoporosis | List with clinical criteria and/or conditions | Complete | ||
| Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
| Targin | Oxycodone HCI / naloxone HCI | Pain, moderate to severe and relief of opioid-induced constipation | Do not list | Complete | ||
| Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Xarelto | Rivaroxaban | Venous thromboembolism, prevention | N/A | Complete | ||
| XGEVA | Denosumab | Prevention of skeletal-related events due to bone metastases from solid tumours | List with clinical criteria and/or conditions | Complete |
Last Updated : May 17, 2024